COMPANY REGISTRATION NUMBER:
07366871
|
Filleted Unaudited Financial Statements |
|
|
Statement of Financial Position |
|
31 July 2025
Fixed assets
|
Investments |
4 |
|
287,175 |
287,175 |
|
|
|
|
|
Current assets
|
Cash at bank and in hand |
27 |
|
140 |
|
|
|
|
|
Creditors: amounts falling due within one year |
5 |
110,630 |
|
110,769 |
|
--------- |
|
--------- |
|
Net current liabilities |
|
110,603 |
110,629 |
|
|
--------- |
--------- |
|
Total assets less current liabilities |
|
176,572 |
176,546 |
|
|
--------- |
--------- |
|
Net assets |
|
176,572 |
176,546 |
|
|
--------- |
--------- |
|
|
|
|
|
Capital and reserves
|
Called up share capital |
|
1,000 |
1,000 |
|
Profit and loss account |
|
175,572 |
175,546 |
|
|
--------- |
--------- |
|
Shareholders funds |
|
176,572 |
176,546 |
|
|
--------- |
--------- |
|
|
|
|
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476
;
-
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements
.
These financial statements were approved by the
board of directors
and authorised for issue on
27 February 2026
, and are signed on behalf of the board by:
Company registration number:
07366871
|
Notes to the Financial Statements |
|
Year ended 31 July 2025
1.
General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 1 Picton Lane, Swansea, SA1 4AF.
2.
Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.
4.
Investments
|
Shares in group undertakings |
|
£ |
|
Cost |
|
|
At 1 August 2024 and 31 July 2025 |
287,175 |
|
--------- |
|
Impairment |
|
|
At 1 August 2024 and 31 July 2025 |
– |
|
--------- |
|
|
|
Carrying amount |
|
|
At 31 July 2025 |
287,175 |
|
--------- |
|
At 31 July 2024 |
287,175 |
|
--------- |
|
|
5.
Creditors:
amounts falling due within one year
|
2025 |
2024 |
|
£ |
£ |
|
Amounts owed to group undertakings and undertakings in which the company has a participating interest |
109,760 |
109,989 |
|
Other creditors |
870 |
780 |
|
--------- |
--------- |
|
110,630 |
110,769 |
|
--------- |
--------- |
|
|
|
6.
Related party transactions
The company was not under control of any one particular party during the period. Ysgol Pharmacy Limited, a UK subsidiary, is owed £109,760 (2024 £109,890) by the Company at the end of the financial year. Management Charges of £1,100 were invoiced to Ysgol Pharmacy Limited during the year.